Clinical Trial Detail

NCT ID NCT04429542
Title Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bicara Therapeutics
Indications

chordoma

stomach cancer

pancreatic cancer

lung squamous cell carcinoma

hepatocellular carcinoma

ovary epithelial cancer

colorectal cancer

anal canal squamous cell carcinoma

thyroid gland anaplastic carcinoma

uveal melanoma

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

glioblastoma multiforme

Advanced Solid Tumor

Therapies

BCA101

BCA101 + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST